Randomization and treatment
inflammation, VKH
INFLAMMATION, DISEASE, REMISSION
Participants were randomly assigned to the biologic (adalimumab) group or the immunosuppressant (cyclosporine) group in a 1:1 ratio, stratified by disease phase (early vs. late) according to the Chinese diagnostic criteriaThe period of remission induction was 26 weeks. Patients in the biologic group received subcutaneous injection with adalimumab at 40 mg every 2 weeks. We followed the practice in some real-world settingsBoth groups additionally received the same corticosteroid regimen. Previous studies have indicated more intensive treatment for early-phase VKH diseaseTopical corticosteroid drops combined with cycloplegic and mydriatic agents were used and adjusted according to the condition of anterior segment inflammation. Topical corticosteroids were tapered to discontinuation over four weeks after the anterior segment inflammation subsided. Prohibited therapies included glucocorticosteroid implant, periocular and intravitreal injections.